Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Micro and nanorobots could transform blood clot treatment

23

Jun 2026

Micro and nanorobots could transform blood clot treatment

Newer tethered devices address some of these limitations: the "milli‑spinner" thrombectomy device applies compressive and shear loading to compact a clot to about 10% of its original volume, enabling ultrafast removal even in pulmonary and cerebral arteries (in vitro and porcine studies).

Circadian rhythm influences calorie burning after eating

23

Jun 2026

Circadian rhythm influences calorie burning after eating

Han-Chow Koh, PhD, and Frank A.J.L. Scheer, PhD, of the Medical Chronobiology Program at the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine, are the co-lead and senior author, respectively, of a paper published in Metabolism, "Constant-routine protocol reveals an endogenous circadian rhythm in diet-induced thermogenesis with a peak in the biological morning."

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.